Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells

Nature Communications

Volumn 4, Issue , 2013, Pages

  Yoshimaru, Tetsuro ^a   Komatsu, Masato ^a   Matsuo, Taisuke ^a   Chen, Yi An ^b   Murakami, Yoichi ^b,h   Mizuguchi, Kenji ^b   Mizohata, Eiichi ^c   Inoue, Tsuyoshi ^c   Akiyama, Miki ^d   Yamaguchi, Rui ^d   Imoto, Seiya ^d   Miyano, Satoru ^d   Miyoshi, Yasuo ^e   Sasa, Mitsunori ^f   Nakamura, Yusuke ^d,g   Katagiri, Toyomasa ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

^f Tokushima Breast Care Clinic   (Japan)

^g UNIVERSITY OF CHICAGO   (United States)

^h TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPORTER; BREFELDIN A INHIBITED GUANINE NUCLEOTIDE EXCHANGE PROTEIN 3; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA ACTIVITY REGULATOR SYNTHETIC PEPTIDE; PROHIBITIN; PROHIBITIN 2; SYNTHETIC PEPTIDE; TAMOXIFEN; UNCLASSIFIED DRUG;

CANCER; DISEASE TREATMENT; DRUG RESISTANCE; ENDOCRINE DISRUPTOR; ESTROGENIC COMPOUND; INHIBITOR; PEPTIDE; TUMOR; WOMENS HEALTH;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; CELL-PENETRATING PEPTIDES; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BINDING; REPRESSOR PROTEINS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84884692673     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3443     Document Type: Article

References (55)

1. McCracken, M. et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese Ethnicities. CA Cancer J. Clin. 57, 190-205 (2007) (Pubitemid 47312080)
2. Jemal, A. et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006)
3. Yager, J. D. & Davidson, N. E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270-282 (2006)
4. Berry, D. A. et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353, 1784-1792 (2005) (Pubitemid 41549890)
5. Green, S. & Chambon, P. Nuclear receptors enhance our understanding of transcription regulation. Trends Genet. 4, 309-314 (2000)
6. Kahlert, S. et al. Estrogen receptor rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 275, 18447-18453 (2000) (Pubitemid 30414803)
7. Simoncini, T. et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538-541 (2000)
8. Castoria, G. et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 20, 6050-6059 (2001) (Pubitemid 33049280)
9. Song, R. X. et al. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor a to the plasma membrane. Proc. Natl Acad. Sci. USA 101, 2076-2081 (2004) (Pubitemid 38229017)
10. Osborne, C. K. & Schiff, R. Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 23, 1616-1622 (2005) (Pubitemid 46211414)
11. Johnston, S. R. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 16, 1979-1987 (2010)
12. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 97, 1652-1662 (2005) (Pubitemid 41672231)
13. Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2, 205-213 (2003)
14. Clarke, R., Leonessa, F., Welch, J. N. & Skaar, T. C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53, 25-71 (2001)
15. Fisher, B., Dignam, J., Bryant, J. & Wolmark, N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684-690 (2001) (Pubitemid 32492809)
16. Ring, A. & Dowsett, M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11, 643-658 (2004) (Pubitemid 40065543)
17. Leary, A. F., Sirohi, B. & Johnston, S. R. Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Res. 9, 112 (2007)
18. Leary, A. F. et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin. Cancer Res. 16, 1486-1497 (2010)
19. Osborne, C. K. et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin. Cancer Res. 17, 1147-1159 (2011)
20. Nishidate, T. et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int. J. Oncol. 25, 797-819 (2004)
21. Kim, J. W. et al. Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 100, 1468-1478 (2009)
22. Montano, M. M. et al. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc. Natl Acad. Sci. USA 96, 6947-6952 (1999) (Pubitemid 29274990)
23. Delage-Mourroux, R. et al. Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. J. Biol. Chem. 275, 35848-35856 (2000)
24. Murakami, Y. & Mizuguchi, K. Applying the naive bayes classifier with kernel density estimation to the prediction of protein-protein interaction sites. Bioinformatics 26, 1841-1848 (2010)
25. Klinge, C. M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29, 2905-2919 (2001) (Pubitemid 32685217)
26. Kushner, P. L. et al. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74, 311-317 (2000)
27. Kurtev, V. et al. Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases. J. Biol. Chem. 279, 24834-24843 (2004) (Pubitemid 38725351)
28. Varlakhabova, N., Snyder, C., Jose, S., Hahm, J. B. & Privalsky, M. L. Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. Mol. Cell Biol. 30, 1434-1445 (2010)
29. Brown, A. M., Jeltsch, J. M., Roberts, M. & Chambon, P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. Natl Acad. Sci. USA 81, 6344-6348 (1984) (Pubitemid 15220836)
30. Altucci, L. et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G (1)-arrested human breast cancer cells. Oncogene 12, 2315-2324 (1996) (Pubitemid 26192711)
31. Dubik, D., Dembinski, T. C. & Shiu, R. P. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 47, 6517-6521 (1987) (Pubitemid 18019647)
32. Jin, V. X., Rabinovich, A., Squazzo, S. L., Green, R. & Farnham, P. J. A computational genomics approach to identify cisregulatory modules from chromatin immunoprecipitation microarray data-a case study using E2F1. Genome Res. 16, 1585-1595 (2006) (Pubitemid 44878497)
33. Yu, W. C., Leung, B. S. & Gao, Y. L. Effects of 17 beta-estradiol on progesterone receptors and the uptake of thymidine in human breast cancer cell line CAMA-1. Cancer Res. 41, 5004-5009 (1981)
34. Welsh, A. W. et al. Cytoplasmic estrogen receptor in breast cancer. Clin. Cancer Res. 18, 118-126 (2012)
35. Mintz, P. J. et al. The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer 113, 1489-1495 (2008)
36. Murphy, L. C., Seekallu, S. V. & Watson, P. H. Clinical significance of estrogen receptor phosphorylation. Endocr. Relat. Cancer 18, R1-R14 (2011)
37. Lannigan, D. A. Estrogen receptor phosphorylation. Steroids 68, 1-9 (2008) (Pubitemid 35418300)
38. Chen, D. et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol. Cell 6, 127-137 (2000)
39. Chen, D., Pace, P. E., Coombes, R. C. & Ali, S. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol. Cell Biol. 19, 1002-1015 (1999) (Pubitemid 29046844)
40. Joel, P. B. et al. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell Biol. 18, 1978-1984 (1998) (Pubitemid 28152646)
41. Rogatsky, I., Trowbridge, J. M. & Garabedian, M. J. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem. 274, 22296-22302 (1999)
42. Arnold, S. F., Melamed, M., Vorojeikina, D. P., Notides, A. C. & Sasson, S. Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol. Endocrinol. 11, 48-53 (1997) (Pubitemid 27021253)
43. Wang, R. A., Mazumdar, A., Vadlamudi, R. K. & Kumar, R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J. 21, 5437-5447 (2001) (Pubitemid 35231023)
44. Taylor, I. W., Hodson, P., Green, M. D. & Sutherland, R. L. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res. 43, 4007-4010 (1983)
45. Oyama, M. et al. Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer. J. Biol. Chem. 286, 818-829 (2011)
46. Fagan, D. H., Uselman, R. R., Sachdev, D. & Yee, D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res. 72, 3372-3380 (2012)
47. Sato, T. et al. The human prohibitin (PHB) gene family and its somatic mutations in human tumours. Genomics 17, 762-764 (1993) (Pubitemid 23282837)
48. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004) (Pubitemid 38174664)
49. Walensky, L. D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004) (Pubitemid 39167667)
50. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 (2009)
51. Abramoff, M. D., Magelhaes, P. J. & Ram, S. J. Image processing with Image J. Biophotonics Int. 11, 36-42 (2004)
52. Shi, J., Blundell, T. L. & Mizuguchi, K. FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structuredependent gap penalties. J. Mol. Biol. 310, 243-257 (2001) (Pubitemid 32619966)
53. McGuffin, L. J., Bryson, K. & Jones, D. T. The PSIPRED protein structure prediction server. Bioinformatics 16, 404-405 (2000) (Pubitemid 30417087)
54. Eswar, N., Eramian, D., Webb, B., Shen, M. Y. & Sali, A. Protein structure modeling with MODELLER. Methods Mol. Biol. 426, 145-159 (2008)
55. Goldenberg, S. J. et al. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 119, 517-528 (2004). (Pubitemid 39482351) Technology Technology